The easy way to boost employee engagement Today more than ever, companies and leaders need a road map to help them boost employee engagement levels. Employee Engagement For Dummies helps employers implement the necessary plans to create and sustain an engaging culture, allowing them to attract and retain the best people while boosting their productivity and creativity. Employee Engagement For Dummies helps you foster employee engagement, a concept that furthers an organization′s interests through ensuring that employees remain involved in, committed to, and fulfilled by their work. It covers: practical steps to boost employee engagement with your company or team; how to engage different generations of employees; the keys to reduce voluntary employee turnover; practical tools to help retain and engage your employees; processes that will boost employee retention and productivity; hiring the best fits from the start; and much more. Helps you recognize and understand the impact of positive employee engagement Helps you attract and retain the best employees Employee Engagement For Dummies is for business leaders at all levels who are looking to better engage their employees and increase morale and productivity.
Prostate Cancer Breakthroughs 2014 takes you through the entire diagnostic process, answering your questions and suggesting others to ask, then describing 12 different treatment choices for you to consider. Studies have proven that most men diagnosed with prostate cancer do not need surgery or radiation treatment. Find out how to determine whether you do or don't and what your other options are.
This thoroughly updated and revised edition of a widely acclaimed book provides concise and authoritative guidance to today's best therapeutic regimens for the diagnosis and treatment of prostate cancer. The authors explain the trends in diagnosis and mortality, new PSA isoforms for diagnosis, PSA screening, chemoprevention, biopsy techniques, sural nerve grafting, and hereditary prostate cancer. Additional chapters reflect progress in the management of locally advanced disease, the use of nomograms to predict outcomes, the medical management of erectile dysfunction, brachytherapy, and deciding between surgery and radiation. A compact disk accompanies the book for downloading the book to a PC or PDA.
"This book admirably covers prostate cancer. It is written in an easily digestible manner for non-experts and emphasizes the importance of a team approach to treatment of patients with this disease."--Doody's Reviews With an emphasis on multidisciplinary collaboration and decision-making, this practical resource reflects the extraordinary advances in the treatment of prostate cancer during the past five years. Approximately thirty international, leading-edge investigators describe the most current evidence-based approaches to prostate cancer treatment. The book provides a comprehensive view of the entire spectrum of prostate cancer management from initial screening through novel and experimental treatments that have the potential for a major impact on practice. The book first reviews fundamental issues including epidemiology, screening, risk reduction, diagnosis and pathologic characterization, staging, and imaging. This includes strategies for improving the accuracy of PSA screening and an update on controversies surrounding the ISUP Modified Gleason Score. The book covers novel molecular and genotype profiling in prostate cancer, including morphometric and systems pathology. Detailed information is provided on radiographic imaging for diagnosis and staging. The treatment sections of the book correspond to the staging of disease. The treatment of localized disease addresses the range of multidisciplinary management options including a discussion of prostate cancer's impact on the quality of life. A detailed review of multimodal therapies (medical, surgical, and radiologic) addresses the treatment of localized advanced disease, and coverage of advanced metastatic prostate cancer reviews current management options including a range of promising novel and experimental agents. The book also discusses counseling the high-risk patient. Several chapters incorporate models of care delivery, patient navigation for multidisciplinary care, genomic and risk assessment, and comparative effects of research in treatment decision-making. The book is designed as a management text for all health care professionals who provide care for prostate cancer patients as well as patients, families, and advocates. Extensive references offer opportunities for additional study. Key Features: Delineates a practical, concise approach to multidisciplinary management of prostate cancer Provides a wide range of perspectives and expertise Written and edited by an international, multidisciplinary team of prostate cancer specialists Focuses on such key issues as special populations, screening controversies, patient counseling, and quality of life Includes discussion of important emerging topics such as gene profiling and targeted therapies and comparative effectiveness data "
Carcinoma of the prostate increasingly dominates the attention of urologists for both scientific and clinical reasons. The search for an explanation and the prediction of the variable behaviour of the malignant prostatic cell continues unabated. The search for more precise tumour staging and more effective treatment is equally vigorous. Editors Andrew Bruce and John Trachtenberg have assembled acknowledged leaders in prostate cancer to present those areas of direct interest to the clinician. There are a number of other topics that might have been considered but most of these, such as experimental tumour models or biochemical factors affecting cell growth, still lack immediate application for the clinician. Carcinoma of the prostate continues to have its highest incidence in the western world, and the difference in comparison with the incidence in the Far East appears to be real and not masked by diagnostic or other factors. A number of other epidemiological aspects need careful analysis: Is the incidence increasing? Is the survival improving? Is the prognosis worse in the younger patient? Epidemiological data are easily misused and misinterpreted so that a precise analysis of the known facts makes an important opening chapter to this book.
Stereotactic body radiation therapy (SBRT) has emerged as an important innovative treatment for various primary and metastatic cancers. This book provides a comprehensive and up-to-date account of the physical/technological, biological, and clinical aspects of SBRT. It will serve as a detailed resource for this rapidly developing treatment modality. The organ sites covered include lung, liver, spine, pancreas, prostate, adrenal, head and neck, and female reproductive tract. Retrospective studies and prospective clinical trials on SBRT for various organ sites from around the world are examined, and toxicities and normal tissue constraints are discussed. This book features unique insights from world-renowned experts in SBRT from North America, Asia, and Europe. It will be necessary reading for radiation oncologists, radiation oncology residents and fellows, medical physicists, medical physics residents, medical oncologists, surgical oncologists, and cancer scientists.
Advances in Cancer Research, Volume 150, the latest release in this ongoing series, covers the relationship(s) between autophagy and senescence, how they are defined, and the influence of these cellular responses on tumor dormancy and disease recurrence. Specific sections in this new release include Autophagy and senescence, converging roles in pathophysiology, Cellular senescence and tumor promotion: role of the unfolded protein response, autophagy and senescence in cancer stem cells, Targeting the stress support network regulated by autophagy and senescence for cancer treatment, Autophagy and PTEN in DNA damage-induced senescence, mTOR as a senescence manipulation target: A forked road, and more. - Addresses the relationship between autophagy and senescence in cancer therapy - Covers autophagy and senescence in tumor dormancy - Explores autophagy and senescence in disease recurrence
This book effectively summarizes our knowledge of recent advances in prostate cancer. It focuses on our state-of-the-art understanding of risk factors, prevention, detection, prognosis and treatment of prostate cancer and identifies basic science findings that are being translated into clinical practice. In addition, the book singles out key areas of research that have potential for clinical translation. Both basic scientists and clinicians will be invited to provide up-to-date reviews in each area of prostate cancer. During the last decade the pace of clinical discovery and the scientific advances in prostate cancer have been very rapid. For instance, currently there are more than 100 drugs in the pharmaceutical pipeline that have the potential for clinical management of prostate cancer. Therefore, it has been very difficult for clinicians and basic scientists to keep pace with the field as a whole. Recently, some of these discoveries are already having an impact on clinical practice. For example, the discovery of the androgen receptor gene amplification in prostate cancer has led to the development of a OC super-antiandrogenOCO, which is being tested in clinical trials. Also, recent knowledge of androgen synthesis in prostate cancer cells has led to clinical trials with steroid-metabolism inhibitors. Finally, robotic surgery has also dramatically changed clinical practice. Thus, this important book serves to provide readers with a one-stop overview of the field of prostate cancer research and its translation into the clinical arena."
A must-have reference, this new edition provides practical information on treatment guidelines, details of diagnosis and therapy, and personal recommendations on patient management from experts in the field. Consistently formatted chapters allow for a user-friendly presentation for quick access of key information by the practicing clinician. Completely updated, this new edition includes all of the latest developments in treatment strategies of medical, surgical and radiation oncologists.
